These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 31092103)
1. GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer. Ma R; Li X; Liu H; Jiang R; Yang M; Zhang M; Wang Y; Zhao Y; Li H Cancer Biol Ther; 2019; 20(9):1206-1212. PubMed ID: 31092103 [TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress. Wang Z; Du T; Dong X; Li Z; Wu G; Zhang R Int J Oncol; 2016 Jun; 48(6):2558-66. PubMed ID: 27035631 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407 [TBL] [Abstract][Full Text] [Related]
8. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1. Chen J; Cui JD; Guo XT; Cao X; Li Q Cancer Med; 2018 Apr; 7(4):1394-1403. PubMed ID: 29493886 [TBL] [Abstract][Full Text] [Related]
9. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Xie C; Jin J; Bao X; Zhan WH; Han TY; Gan M; Zhang C; Wang J Oncotarget; 2016 Jan; 7(1):610-21. PubMed ID: 26575584 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells. Yang Z; Hu X; Zhang S; Zhang W; Tam KY Eur J Pharmacol; 2017 Nov; 815():80-87. PubMed ID: 28870456 [TBL] [Abstract][Full Text] [Related]
12. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway. Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157 [TBL] [Abstract][Full Text] [Related]
13. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression. Huang S; Zhang J; Wu X; Liang B; Pang N; Yang L; Zhang Z Life Sci; 2024 Aug; 351():122849. PubMed ID: 38897346 [TBL] [Abstract][Full Text] [Related]
14. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Li F; Zhu T; Cao B; Wang J; Liang L Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888 [TBL] [Abstract][Full Text] [Related]
15. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Zhang Z; Lian X; Xie W; Quan J; Liao M; Wu Y; Yang ZZ; Wang G Sci Rep; 2020 Dec; 10(1):20924. PubMed ID: 33262410 [TBL] [Abstract][Full Text] [Related]
16. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation. Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221 [TBL] [Abstract][Full Text] [Related]
17. CD147-mediated glucose metabolic regulation contributes to the predictive role of Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488 [TBL] [Abstract][Full Text] [Related]
18. Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway. Hong SW; Park NS; Noh MH; Shim JA; Ahn BN; Kim YS; Kim D; Lee HK; Hur DY Lung Cancer; 2017 Apr; 106():115-124. PubMed ID: 28285685 [TBL] [Abstract][Full Text] [Related]
19. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647 [TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]